I've sat in boardrooms where prevention budgets are the first thing cut and treatment costs are treated as inevitable. The framing is backwards. Prevention isn't an expense you can defer. It's the only intervention that gets cheaper the earlier you start - and more expensive the longer you wait.
What You Need to Know
- Preventive health interventions consistently show positive ROI when measured over 5-10 year horizons, but most funding models operate on 1-2 year budget cycles
- New Zealand spends approximately 2% of its health budget on prevention, compared to 70%+ on treatment of conditions that are often preventable
- The economic argument for prevention strengthens as data tools enable earlier identification of at-risk individuals and more targeted interventions
- The barrier isn't evidence - it's time horizon mismatch between when prevention is funded and when returns materialise
The Accounting Illusion
Here's how health economics works in practice. Treatment costs show up as line items in this year's budget. Prevention savings show up as costs that didn't happen in future years' budgets. The treatment is visible. The prevention is invisible. And invisible savings don't get funded.
This isn't an insight problem. The data is clear. It's an incentive problem.
$5.60
estimated return for every $1 invested in workplace chronic disease prevention programmes over a 5-year period
Source: PwC, Workplace Wellness in Australia and New Zealand, 2019
A health system that spends $100 million treating type 2 diabetes could spend a fraction of that on metabolic risk screening and lifestyle intervention, catching the condition years before it develops. The maths works. The budget cycle doesn't.
The New Zealand Numbers
New Zealand's health spending is heavily weighted toward treatment. We're not alone in this - most health systems globally have the same imbalance - but the gap is stark.
Our public health system manages an ageing population, rising chronic disease rates, and increasing demand on acute services. The response, year after year, is to increase treatment capacity. More hospital beds. More specialists. More procedures.
~2%
of New Zealand's total health expenditure directed toward organised prevention and public health programmes
Source: OECD Health Statistics, 2024
Two percent on prevention. The remaining ninety-eight percent is largely spent managing conditions that, in many cases, were detectable years before they required treatment.
This isn't a criticism of the people working in the health system. They're managing overwhelming demand with inadequate resources. It's a criticism of a funding model that perpetually prioritises the urgent over the important.
What Prevention Economics Actually Look Like
The economic case for prevention isn't theoretical. It's been measured repeatedly.
Cardiovascular prevention. Statin therapy and blood pressure management for high-risk individuals costs roughly $3,000-5,000 per person annually. A heart attack costs $50,000-100,000 in acute care alone, before counting ongoing management, rehabilitation, and lost productivity.
Diabetes prevention. Structured lifestyle intervention programmes for pre-diabetic individuals cost roughly $500-1,500 per person annually. Managing established type 2 diabetes costs $5,000-10,000 per person annually, rising dramatically with complications.
Mental health early intervention. Early access to psychological support costs a fraction of acute mental health crisis intervention, hospitalisation, and long-term disability support.
In every case, the prevention investment is smaller than the treatment cost. The challenge is that prevention requires investing now for returns that materialise in 3-10 years.
We don't question whether maintaining a building is cheaper than rebuilding it after it collapses. But we somehow debate whether maintaining human health is cheaper than treating disease after it develops.
Jay Harrison
Health Technology Advisory
The Data Unlock
What's changed in the last five years is our ability to identify who needs prevention most.
Previously, preventive health was largely population-wide: public health campaigns, screening programmes at arbitrary age thresholds, general lifestyle advice. These have value, but they're blunt instruments.
Today, genetic risk profiling, biomarker tracking, wearable data integration, and AI-powered risk modelling allow us to identify high-risk individuals years before they'd qualify for clinical intervention under current guidelines.
A 35-year-old with elevated polygenic risk for cardiovascular disease, early metabolic drift visible in biomarkers, and a family history that wasn't captured in their clinical record - that person wouldn't trigger any flags in the current system. They'd be invisible until their first cardiac event at 55.
With the right data tools, that same person is identifiable today. And the interventions at 35 - lifestyle modification, pharmacogenomic-guided preventive medication, targeted monitoring - are orders of magnitude cheaper than the interventions at 55.
The Funding Model Problem
If the economics are clear, why doesn't prevention get funded?
Short budget cycles. Health budgets operate annually. Prevention returns materialise over 5-10 years. A health minister investing heavily in prevention won't see the results during their term.
Invisible returns. A disease prevented doesn't generate a hospital record, an insurance claim, or a news story. It's a non-event. Nobody gets credit for something that didn't happen.
Fragmented beneficiaries. The organisation that funds prevention (employer, insurer, public health system) may not be the one that benefits from reduced treatment costs. This misalignment kills investment incentives.
Treatment industry momentum. Treatment generates revenue for hospitals, pharmaceutical companies, device manufacturers, and specialists. Prevention generates revenue for almost nobody at scale. The economic incentives favour treatment.
None of these barriers are insurmountable. They require deliberate policy and funding design that accounts for prevention's economic characteristics: upfront investment, delayed return, distributed benefit.
What Would Change
If New Zealand shifted even 5% of health spending from treatment to targeted prevention - not generic public health campaigns, but data-informed, risk-stratified prevention programmes - the downstream effects would compound.
Fewer hospital admissions for preventable conditions. Less pressure on an overstretched specialist workforce. Longer healthspan for individuals, meaning more years of economic productivity and less years of costly care.
The first step is reframing the conversation. Prevention isn't an expense to be debated in budget season. It's an investment with measurable, compounding returns. The organisations and health systems that understand this will be the ones still solvent in twenty years.